02/06/17 - Lab study shows: A protein called PERK may be a target for treating progressive supranuclear palsy
DZNE scientists have discovered a molecular mechanism that may help in the search for effective treatments of progressive supranuclear palsy (PSP). Their study focusses on a protein called PERK.
01/12/17 - Research project on precision medicine is funded by the Innovation Fund with 1.5 million euros
Scientists from BfArM and the DZNE will be working together and in cooperation with the statutory health insurance company Techniker Krankenkasse to investigate the influence of pharmacogenetic factors on the effectiveness and safety of drug therapies.